Warning: The NCBI web site requires JavaScript to function. more...

Sign in to NCBI

PubMed

US National Library of Medicine National Institutes of Health

Create RSS
RSS Settings
- Search: Bossenmaier B[au]
- Number of items displayed:
- Feed name:
Create alert
Advanced
Help

Search results

Items: 33

Select item 315261591.

DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.

Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C.

MAbs. 2019 Nov-Dec;11(8):1402-1414. doi: 10.1080/19420862.2019.1661736. Epub 2019 Sep 17.

PMID:: 31526159

Free PMC Article

Similar articles

Select item 308978082.

Acquired Resistance to Antibody-Drug Conjugates.

Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G.

Cancers (Basel). 2019 Mar 20;11(3). pii: E394. doi: 10.3390/cancers11030394. Review.

PMID:: 30897808

Free PMC Article

Similar articles

Select item 308971763.

Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.

Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, Elschenbroich S, Klammer M, Blackler A, Liao WL, Tian Y, Friess T, Bossenmaier B, Dietmann G, Schaab C, Hembrough T, Ceppi M.

PLoS One. 2019 Mar 21;14(3):e0213892. doi: 10.1371/journal.pone.0213892. eCollection 2019.

PMID:: 30897176

Free PMC Article

Similar articles

Select item 286740834.

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.

Leshem Y, O'Brien J, Liu X, Bera TK, Terabe M, Berzofsky JA, Bossenmaier B, Niederfellner G, Tai CH, Reiter Y, Pastan I.

Cancer Immunol Res. 2017 Aug;5(8):685-694. doi: 10.1158/2326-6066.CIR-16-0330. Epub 2017 Jul 3.

PMID:: 28674083

Free PMC Article

Similar articles

Select item 286004765.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

PMID:: 28600476

Similar articles

Select item 284939336.

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B.

PLoS One. 2017 May 11;12(5):e0177331. doi: 10.1371/journal.pone.0177331. eCollection 2017.

PMID:: 28493933

Free PMC Article

Similar articles

Select item 275075377.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

PMID:: 27507537

Free PMC Article

Similar articles

Select item 264637098.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

PMID:: 26463709

Similar articles

Select item 257020499.

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody.

Meneses-Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B.

Cancer Chemother Pharmacol. 2015 Apr;75(4):837-50. doi: 10.1007/s00280-015-2697-8. Epub 2015 Feb 22.

PMID:: 25702049

Free PMC Article

Similar articles

Select item 2565869710.

Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map.

Peess C, von Proff L, Goller S, Andersson K, Gerg M, Malmqvist M, Bossenmaier B, Schräml M.

PLoS One. 2015 Feb 6;10(2):e0116870. doi: 10.1371/journal.pone.0116870. eCollection 2015.

PMID:: 25658697

Free PMC Article

Similar articles

Select item 2487071911.

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Abiraj K, Schröder CP, Pot L, Bossenmaier B, Thomas M, Hölzlwimmer G, Friess T, Kosterink JG, de Vries EG.

MAbs. 2014 Jul-Aug;6(4):1051-8. doi: 10.4161/mabs.29097. Epub 2014 May 7.

PMID:: 24870719

Free PMC Article

Similar articles

Select item 2452999112.

Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation.

van Dieck J, Schmid V, Heindl D, Dziadek S, Schraeml M, Gerg M, Massoner P, Engel AM, Tiefenthaler G, Vural S, Stritt S, Tetzlaff F, Soukupova M, Kopetzki E, Bossenmaier B, Thomas M, Klein C, Mertens A, Heller A, Tacke M.

Chem Biol. 2014 Mar 20;21(3):357-68. doi: 10.1016/j.chembiol.2013.12.018. Epub 2014 Feb 13.

PMID:: 24529991

Similar articles

Select item 2405514113.

Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.

Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R, Bossenmaier B.

Mol Oncol. 2013 Dec;7(6):1142-51. doi: 10.1016/j.molonc.2013.08.009. Epub 2013 Sep 3.

PMID:: 24055141

Free PMC Article

Similar articles

Select item 2378034414.

RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, Hopfner KP, Niederfellner G, Bossenmaier B.

Cancer Res. 2013 Aug 15;73(16):5183-94. doi: 10.1158/0008-5472.CAN-13-0099. Epub 2013 Jun 18.

PMID:: 23780344

Similar articles

Select item 2330086015.

Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.

Kollmorgen G, Bossenmaier B, Niederfellner G, Häring HU, Lammers R.

PLoS One. 2012;7(12):e53050. doi: 10.1371/journal.pone.0053050. Epub 2012 Dec 31.

PMID:: 23300860

Free PMC Article

Similar articles

Select item 2320903116.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

PMID:: 23209031

Similar articles

Select item 2297619717.

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C, Brinkmann U.

Protein Eng Des Sel. 2012 Oct;25(10):571-80. Epub 2012 Sep 13.

PMID:: 22976197

Free PMC Article

Similar articles

Select item 1993433318.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597.

PMID:: 19934333

Similar articles

Select item 1578425919.

The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity.

Wisniewska M, Bossenmaier B, Georges G, Hesse F, Dangl M, Künkele KP, Ioannidis I, Huber R, Engh RA.

J Mol Biol. 2005 Apr 15;347(5):1005-14.

PMID:: 15784259

Similar articles

Select item 1086603920.

Serine residues 1177/78/82 of the insulin receptor are required for substrate phosphorylation but not autophosphorylation.

Bossenmaier B, Strack V, Stoyanov B, Krützfeldt J, Beck A, Lehmann R, Kellerer M, Klein H, Ullrich A, Lammers R, Häring HU.

Diabetes. 2000 Jun;49(6):889-95.

PMID:: 10866039

Similar articles

Select item 1081923721.

Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms beta2 and theta.

Strack V, Hennige AM, Krützfeldt J, Bossenmaier B, Klein HH, Kellerer M, Lammers R, Häring HU.

Diabetologia. 2000 Apr;43(4):443-9.

PMID:: 10819237

Similar articles

Select item 1033811422.

The inhibitory effect of 2-deoxyglucose on insulin receptor autophosphorylation does not depend on known serine phosphorylation sites or other conserved serine residues of the receptor beta-subunit.

Strack V, Bossenmaier B, Stoyanov B, Mosthaf L, Kellerer M, Lammers R, Häring HU.

FEBS Lett. 1999 Apr 23;449(2-3):111-4.

PMID:: 10338114

Similar articles

Select item 956685223.

The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin.

Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring HU.

Horm Metab Res. 1998 Mar;30(3):123-9.

PMID:: 9566852

Similar articles

Select item 934959324.

A 973 valine to methionine mutation of the human insulin receptor: interaction with insulin-receptor substrate-1 and Shc in HEK 293 cells.

Strack V, Bossenmaier B, Stoyanov B, Mushack J, Häring HU.

Diabetologia. 1997 Oct;40(10):1135-40.

PMID:: 9349593

Similar articles

Select item 934530125.

Impact of mutations at different serine residues on the tyrosine kinase activity of the insulin receptor.

Strack V, Stoyanov B, Bossenmaier B, Mosthaf L, Kellerer M, Häring HU.

Biochem Biophys Res Commun. 1997 Oct 9;239(1):235-9.

PMID:: 9345301

Similar articles

Select item 924311026.

Protein kinase C isoforms beta 1 and beta 2 inhibit the tyrosine kinase activity of the insulin receptor.

Bossenmaier B, Mosthaf L, Mischak H, Ullrich A, Häring HU.

Diabetologia. 1997 Jul;40(7):863-6.

PMID:: 9243110

Similar articles

Select item 866591827.

Bradykinin induces tyrosine phosphorylation in human foreskin fibroblasts and 293 cells transfected with rat B2 kinin receptor.

Tippmer S, Bossenmaier B, Häring H.

Eur J Biochem. 1996 Mar 15;236(3):953-9.

PMID:: 8665918

Similar articles

Select item 861788028.

Tumor necrosis factor-alpha- and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling.

Kroder G, Bossenmaier B, Kellerer M, Capp E, Stoyanov B, Mühlhöfer A, Berti L, Horikoshi H, Ullrich A, Häring H.

J Clin Invest. 1996 Mar 15;97(6):1471-7.

PMID:: 8617880

Free PMC Article

Similar articles

Select item 852979129.

Modulation of insulin receptor signaling. Potential mechanisms of a cross talk between bradykinin and the insulin receptor.

Häring HU, Tippmer S, Kellerer M, Mosthaf L, Kroder G, Bossenmaier B, Berti L.

Diabetes. 1996 Jan;45 Suppl 1:S115-9. Review.

PMID:: 8529791

Similar articles

Select item 778962930.

Acute hyperglycemia provides an insulin-independent inducer for GLUT4 translocation in C2C12 myotubes and rat skeletal muscle.

Galante P, Mosthaf L, Kellerer M, Berti L, Tippmer S, Bossenmaier B, Fujiwara T, Okuno A, Horikoshi H, Häring HU.

Diabetes. 1995 Jun;44(6):646-51.

PMID:: 7789629

Similar articles

Select item 786763931.

C-terminus or juxtamembrane deletions in the insulin receptor do not affect the glucose-dependent inhibition of the tyrosine kinase activity.

Mosthaf L, Berti L, Kellerer M, Mushack J, Seffer E, Bossenmaier B, Coghlan M, Siddle K, Ullrich A, Häring HU.

Eur J Biochem. 1995 Feb 1;227(3):787-91.

PMID:: 7867639

Similar articles

Select item 769367132.

Differential activities of protein tyrosine phosphatases in intact cells.

Lammers R, Bossenmaier B, Cool DE, Tonks NK, Schlessinger J, Fischer EH, Ullrich A.

J Biol Chem. 1993 Oct 25;268(30):22456-62.

PMID:: 7693671

Similar articles

Select item 768993533.

Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia.

Bühring HJ, Herbst R, Kostka G, Bossenmaier B, Bartke I, Kropshofer H, Kalbacher H, Busch FW, Müller CA, Schlessinger J, et al.

Cancer Res. 1993 Sep 15;53(18):4424-31.

PMID:: 7689935

Similar articles

Supplemental Content

Filters: Manage Filters

You are here: NCBI > Literature > PubMed